Clinicians struggle to subjectively interpret fetal heart rate patterns, a 50-‐year-‐old technology that has an 89% false positive rate for detecting fetal distress. This ambiguity results in changes to patient care, including cesarean sections, which are later shown to be unnecessary. This has health care implications for mother and child while driving up health care costs. Currently there is no commercially available method to measure fetal oxygenation during birth. Our technology directly determines the fetal oxygen level using a safe, external, single-‐use sensor that complements existing fetal Doppler, and integrates seamlessly into the current monitoring system. It has the potential to become the standard of care for fetal monitoring during childbirth.
Raydiant Oximetry, Inc. has developed a safe and non-‐invasive technology that directly monitors a babies’ oxygenation during childbirth. For obstetric providers who are dissatisfied with current fetal heart rate monitoring systems, this technology leads to better-‐informed decision-‐making and better patient care.